AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis

NEXT STORY
NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases
PREV STORY
Predictive Technology Group Reports Fiscal Year 2019 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

AnaptysBio Reports Positive Topline Data from Interim Analysis of GALLOP Phase 2 Clinical Trial of ANB019 Monotherapy in Moderate-to-Severe Generalized Pustular Psoriasis

NEXT STORY
NewLink Genetics and Lumos Pharma Enter into Merger Agreement to Form Biopharmaceutical Company Focused on Developing Therapies to Treat Rare Diseases
PREV STORY
Predictive Technology Group Reports Fiscal Year 2019 Financial Results
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ADMA Biologics Provides Corporate Update and Reports Third Quarter 2017 Financial Results

RAMSEY, N.J., Nov. 03, 2017 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) (“ADMA” or ...

author_avatar
NASDAQ Market News

Athenex, Inc. Announces First Quarter 2018 Results

Significant Clinical Milestones and Record Revenue Mark Strong Start to Fiscal 2018 First Quarter ...

author_avatar
NASDAQ Market News

RECORDATI: POSITIVE RESULTS FROM THE PHASE III LINC 4 STUDY PRESENTED AT THE ENDOCRINE SOCIETY’S ANNUAL MEETING REINFORCE THE EFFICACY AND SAFETY OF ISTURISA® (OSILODROSTAT) IN CUSHING’S DISEASE

author_avatar
NASDAQ Market News